Dabigatran Level Before Reversal Can Predict Hemostatic Effectiveness of Idarucizumab in a Real-World Setting

Dabigatran Level Before Reversal Can Predict Hemostatic Effectiveness of Idarucizumab in a Real-World Setting

Background: Idarucizumab has been included in guidelines for the management of bleeding or surgical procedure in dabigatran-treated patients without need for biological monitoring. The aim of the study was to assess the prognostic value of dabigatran plasma level before reversal to test the hemostat...

Full description

Bibliographic Details
Main Authors: Nicolas Gendron, Richard Chocron, Paul Billoir, Julien Brunier, Laurence Camoin-Jau, Marie Tuffigo, Dorothée Faille, Dorian Teissandier, Juliette Gay, Emmanuelle de Raucourt, Ludovic Suner, Corentin Bonnet, Anne-Céline Martin, Dominique Lasne, Chayma Ladhari, Aurélien Lebreton, Laurent Bertoletti, Nadine Ajzenberg, Pascale Gaussem, Pierre-Emmanuel Morange, Véronique Le Cam Duchez, Alain Viallon, Pierre-Marie Roy, Agnès Lillo-le Louët, David M. Smadja
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-12-01
Series:Frontiers in Medicine
Subjects:
idarucizumab
dabigatran
reversal
bleeding
hemostatic effectiveness
rebound
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2020.599626/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2020.599626/full

Similar Items